Long-term administration of interferon-α in non-responder patients with chronic hepatitis C: Follow-up of liver fibrosis over 5 years

Journal of Viral Hepatitis

Volumn 6, Issue 2, 1999, Pages 125-133

  Guerret, S ^a   Desmouliere A ^b   Chossegros, P ^c   Costa, A M A ^b   Badid, C ^b   Trepo C ^c   Grimaud, J A ^d   Chevallier, M ^a  

^a LMM Laboratoire Marcel Merieux   (France)

^b INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^c HÔTEL DIEU   (France)

^d INSTITUT PASTEUR   (France)

Author keywords

Hepatitis C; IFN ; Liver fibrosis; Non responder

Indexed keywords

COLLAGEN; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LONG TERM CARE; MALE; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME;

ADULT; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIME FACTORS; VIRAL LOAD;

EID: 0033050596     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1999.00148.x     Document Type: Article

References (53)

1. Realdi G, Alberti A, Rugge M et al. Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis. Gut 1982; 23: 270-275.
2. Trepo C, Lindberg J. Non-A, non-B, hepatitis. Scand J Gastroenterol 1982; 77 (suppl 77): 75-91.
3. Dienstag JL. Non-A, non-B, hepatitis I. Recognition, epidemiology, and clinical features. Gastroenterology 1983; 85: 439-462.
4. Wejstål R, Lindberg J, Lundin P, Norkrans G. Chronic non-A, non-B hepatitis: a long-term follow-up study in 49 patients. Scand J Gastroenterol 1987; 22: 1115-1122.
5. Mattsson L, Weiland O, Glaumann H. Chronic non-A, non-B hepatitis developed after transfusions, illicit self-injections or sporadically: outcome during longterm follow-up: a comparison. Liver 1989; 9: 120-127.
6. Hopf U, Möller B, Kuther D et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus (HCV). J Hepatol 1990; 10: 69-76.
7. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
8. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315: 1575-1578.
9. Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
10. Di Bisceglie AM, Martin P, Kassianides C et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506-1510.
11. Jacyna MR, Brooks MG, Loke RHT, Main J, Murray-Lyon IM, Thomas HC. Randomized controlled trial of interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. BMJ 1989; 298: 80-82.
12. Schvarcz R, Weiland O, Wejstål R, Norkrang G, Frýden A, Foberg U. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttranfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 1989; 21: 617-625.
13. Weiland O, Schvarcz R, Wejstål R, Norkrans G, Foberg U, Fryden A. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B hepatitis: interim results of a randomized controlled open study. Scand J Infect Dis 1989; 21: 127-132.
14. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
15. Knodell RG, Ishak KS, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
16. Degott C, Giostra E, Chevallier M, Grimaud JA, Trepo C, Marcellin P. Effets de l'interféron alpha sur les lésions histologiques de l'hépatite chronique C: recherche de lésions prédictives de la réponse au traitement (abstr). Gastroenterol Clin Biol 1991; 15: 895.
17. Cammà C, Craxi A, Tiné F et al. Predictors of response to alpha interferon (IFN) in chronic hepatitis C: a multivariate analysis on 361 treated patients (abstr). J Hepatol 1992; 17 (suppl 1): S20.
18. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J. Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17: 390-396.
19. Jimenez W, Pares A, Caballeria J et al. Measurement of fibrosis in needle liver biopsies: evaluation of a colorimetric method. Hepatology 1985; 5: 815-818.
20. 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993; 18: 1345-1349.
21. Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstål R, Frýden A. Histological outcome in interferon alpha-2b treated patients with chronic posttransfusion non-A, non-B hepatitis. Liver 1991; 11: 30-38.
22. Cammà C, Di Marco V, Lo Iacono O et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531-537.
23. Castilla A, Prieto J, Fausto N. Transforming growth factor beta 1 and alpha in chronic liver disease. Effects of interferon alpha therapy. N Engl J Med 1991; 324: 933-940.
24. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semi-quantitative scoring system (SSS) for evaluation of hepatic fibrosis on needle liver biopsies: comparison with morphometric studies. Hepatology 1994; 20: 349-355.
25. James J, Bosch KS, Zuyderhoudt FMJ, Houtkooper JM, Van Gool J. Histophotometric estimation of volume density of collagen as an indication of fibrosis in rat liver. Histochemistry 1986; 85: 129-133.
26. Esterre P, Guerret S, Grimaud JA. Application of image analysis to the study of skin granulomas. Anal Cell Pathol 1995; 8: 191-201.
27. Shindo M, Di Bisceglie AM, Cheung L et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700-704.
28. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992; 15: 1013-1016.
29. Magrin S, Craxi A, Fabiano C et al. Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. J Med Virol 1992; 38: 200-206.
30. Weiland O, Schvarcz R, Wejstål R, Norkrans G, Frýden A. Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alpha-2b: Swedish experience. J Hepatol 1990; 11: S57-S62.
31. Marcellin P, Boyer N, Giostra E et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393-397.
32. Fenoglio LM, Peano GM, Gallo V, Menardi G, Chiandussi L, Molinatti GM. Lymphoblastoid interferon retreatment in chronic active hepatitis C not responding to α-recombinant interferon [abstract]. Hepatology 1992; 16: 202A.
33. Brouwer JT, Kleter GEM, Elewaut A, Chamuleau RAFM, Michielsen P, Heitjink RA. Initial non response to interferon in chronic hepatitis C. induction of ALT normalization and HCV-RNA disappearance by high-dose interferon therapy (abstr). J Hepatol 1992; 16 (suppl 1): S49.
34. Bosch O, Tapia L, Quiroga JA, Carreno V. An escalating dose regime of recombinant interferon-alpha 2a in the treatment of chronic hepatitis C. J Hepatol 1993; 17: 146-149.
35. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-165.
36. Reichard O, Foberg U, Frýden A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α-2b for 60 weeks. Hepatology 1994; 19: 280-285.
37. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC, for the Australia hepatitis C study group. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995; 23: 487-496.
38. Saracco G, Rosina F, Torrani Cerenzia MR et al. A randomized controlled trial of interferon alpha-2b as therapy for chronic non-A, non-B hepatitis. J Hepatol 1990; 11: S43-S49.
39. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM and The French Group for the Study of NANB/C Chronic Hepatitis Treatment. Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 1994; 106: 686-690.
40. Davis GL, Lindsay K, Albrecht J et al. Predictors of response to recombinant alpha interferon (rIFN) treatment in patients with chronic hepatitis C (abstr). Hepatology 1990; 12: 905.
41. Omata M, Ito Y, Yokosuka O et al. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant α-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991; 36: 1217-1222.
42. Pagliaro L, Craxi A, Cammá C et al. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-828.
43. Cammà C, Giunta M, Linea C, Pagliaro L. The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997; 26: 1187-1199.
44. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of hepatitis C. Effects of dose and duration. Hepatology 1996; 24: 778-789.
45. Duchatelle V, Marcellin P, Giostra E et al. Changes in liver fibrosis at the end and 6-18 months after alpha interferon therapy in patients with chronic hepatitis: quantitative assessment by a morphometric method. Hepatology 1998; 29: 20-28.
46. Chow WC, Boyer N, Pouteau M et al. Re-treatment with interferon-α of patients with chronic hepatitis C. Hepatology 1998; 27: 1144-1148.
47. Mallat A, Preaux AM, Blazejewski S et al. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995; 21: 1003-1010. .
48. Blazejewski S, Préaux AM, Mallat A et al. Human myofibroblast like cells obtained by outgrowth are representative of the fibrogenic cells in the liver. Hepatology 1995; 22: 788-797.
49. Knittel T, Müller L, Saile B, Ramadori G. Effect of tumour necrosis factor-α on proliferation, activation and protein synthesis of rat hepatic stellate cells. Hepatology 1997; 27: 1067-1080.
50. Arthur MJP. Collagenases and liver fibrosis. J Hepatol 1995; 22: 43-48.
51. Schmitt-Gräff A, Desmoulière A, Gabbiani G. Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch 1994; 425: 3-24.
52. Horn T, Junge J, Christoffersen P. Early alcoholic liver injury. Activation of lipocytes in acinar zone 3 and correlation to degree of collagen formation in the Disse space. J Hepatol 1986; 3: 333-340.
53. Gressner AM, Bachem MG. Cellular sources of non collagenous matrix proteins: role of fat-storing cells in fibrogenesis. Semin Liver Dis 1990; 10: 30-45.